City Therapeutics' Mei Baisong holds 228,743 shares

Q: How many shares and options does CTY Chief Medical Officer Mei Baisong report?

Mei Baisong reports direct ownership of 228,743 common shares and two stock options covering 131,937 and 56,978 common shares, at exercise prices of $1.84 and $5.36, respectively. The options expire May 12, 2035, and June 2, 2036, respectively.

Q: What are the vesting terms for Mei Baisong's CTY stock options?

The option covering 131,937 shares had 25% vest on March 31, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each vesting date. The option covering 56,978 shares vests in 48 equal monthly installments following June 3, 2026, also subject to continued service on each vesting date.

City Therapeutics, Inc. (CTY) reports Chief Medical Officer Mei Baisong directly holding 228,743 common shares as of October 15, 2026, along with two stock options for common stock.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

City Therapeutics, Inc. (CTY) reports Chief Medical Officer Mei Baisong directly holding 228,743 common shares as of October 15, 2026, along with two stock options for common stock. One option covers 131,937 shares at an exercise price of $1.84 and expires May 12, 2035; the other covers 56,978 shares at $5.36 and expires June 2, 2036.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Mei Baisong

Role Chief Medical Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) ^F1	--	--	--
holding	Stock Option (Right to Buy) ^F2	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 188,915 contracts (Direct); Common Stock — 228,743 shares (Direct)

Footnotes (2)

F1. 25% of the shares underlying this option vested on March 31, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2. The shares underlying this option vest in 48 equal monthly installments following June 3, 2026, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Direct common shares: 228,743 shares Option underlying shares: 131,937 shares Exercise price: $1.84 per share +4 more

7 metrics

Direct common shares 228,743 shares Reported October 15, 2026

Option underlying shares 131,937 shares Option expiring May 12, 2035

Exercise price $1.84 per share Option expiring May 12, 2035

Option expiration date May 12, 2035 Option covering 131,937 shares

Option underlying shares 56,978 shares Option expiring June 2, 2036

Exercise price $5.36 per share Option expiring June 2, 2036

Option expiration date June 2, 2036 Option covering 56,978 shares

Key Terms

Stock Option (Right to Buy), equal monthly installments, continued service

3 terms

Stock Option (Right to Buy) technical

"Stock Option (Right to Buy)"

equal monthly installments technical

"vesting in 36 equal monthly installments"

continued service technical

"subject to the Reporting Person's continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares and options does CTY Chief Medical Officer Mei Baisong report?

Mei Baisong reports direct ownership of 228,743 common shares and two stock options covering 131,937 and 56,978 common shares, at exercise prices of $1.84 and $5.36, respectively. The options expire May 12, 2035, and June 2, 2036, respectively.

What are the vesting terms for Mei Baisong's CTY stock options?

The option covering 131,937 shares had 25% vest on March 31, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each vesting date. The option covering 56,978 shares vests in 48 equal monthly installments following June 3, 2026, also subject to continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/17/2026 - 08:37 PM EDT Accepted by SEC EDGAR 10/15/2026 - 09:05 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mei Baisong

(Last)

(First)

(Middle)

399 BINNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02142

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/15/2026

3. Issuer Name and Ticker or Trading Symbol
CITY THERAPEUTICS, INC. [ CTY ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	228,743	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	05/12/2035	Common Stock	131,937	$1.84	D
Stock Option (Right to Buy)	⁽²⁾	06/02/2036	Common Stock	56,978	$5.36	D

Explanation of Responses:

1. 25% of the shares underlying this option vested on March 31, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

2. The shares underlying this option vest in 48 equal monthly installments following June 3, 2026, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Mary Beth DeLena, Attorney-in-Fact	10/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR